Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Nesnas

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The Journal of Investigative Dermatology|May 5, 2023
Risk of Melanoma and Nonmelanoma Skin Cancer in People with Vitiligo: United Kingdom Population-Based Cohort StudyJohn Ferguson, Viktoria Eleftheriadou, John Nesnas
Antibiotics (Basel, Switzerland)|January 21, 2023
Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile InfectionLaura Whitney, John Nesnas, Timothy Planche
The Journal of Investigative Dermatology|November 17, 2023
Response to Venables and LevellJohn Ferguson, Viktoria Eleftheriadou, John Nesnas
Bjpsych Open|October 21, 2022
The mental health associations of vitiligo: UK population-based cohort studyAndrew R Thompson, Viktoria Eleftheriadou, John Nesnas
The British Journal of Dermatology|July 17, 2024
The lifetime risk and impact of vitiligo across sociodemographic groups: a UK population-based cohort studyViktoria Eleftheriadou, Alia Ahmed, John Nesnas, et al.
The British Journal of Dermatology|August 6, 2024
Lifetime incidence and healthcare disparities in alopecia areata: a UK population-based cohort studyAndrew R Thompson, Christos Tziotzios, John Nesnas, et al.
The Journal of Dermatological Treatment|April 10, 2023
Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trialCarsten Flohr, Michael J Cork, Michael R Ardern-Jones, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The Journal of Investigative Dermatology|May 5, 2023
Risk of Melanoma and Nonmelanoma Skin Cancer in People with Vitiligo: United Kingdom Population-Based Cohort StudyJohn Ferguson, Viktoria Eleftheriadou, John Nesnas
Antibiotics (Basel, Switzerland)|January 21, 2023
Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile InfectionLaura Whitney, John Nesnas, Timothy Planche
The Journal of Investigative Dermatology|November 17, 2023
Response to Venables and LevellJohn Ferguson, Viktoria Eleftheriadou, John Nesnas
Bjpsych Open|October 21, 2022
The mental health associations of vitiligo: UK population-based cohort studyAndrew R Thompson, Viktoria Eleftheriadou, John Nesnas
The British Journal of Dermatology|July 17, 2024
The lifetime risk and impact of vitiligo across sociodemographic groups: a UK population-based cohort studyViktoria Eleftheriadou, Alia Ahmed, John Nesnas, et al.
The British Journal of Dermatology|August 6, 2024
Lifetime incidence and healthcare disparities in alopecia areata: a UK population-based cohort studyAndrew R Thompson, Christos Tziotzios, John Nesnas, et al.
The Journal of Dermatological Treatment|April 10, 2023
Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trialCarsten Flohr, Michael J Cork, Michael R Ardern-Jones, et al.
Pageof 1